KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $1.1 million as the latest value for Q4 2017.

  • On a quarterly basis, Non-Current Deffered Revenue fell 23.45% to $1.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was $1.1 million, a 23.45% decrease, with the full-year FY2017 number at $1.1 million, down 23.45% from a year prior.
  • Non-Current Deffered Revenue was $1.1 million for Q4 2017 at Supernus Pharmaceuticals, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.7 million in Q1 2016 to a low of $738000.0 in Q2 2013.
  • A 5-year average of $1.3 million and a median of $1.3 million in 2014 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 358.58% in 2013, then dropped 23.45% in 2017.
  • Supernus Pharmaceuticals' Non-Current Deffered Revenue stood at $1.4 million in 2013, then dropped by 10.09% to $1.3 million in 2014, then increased by 9.11% to $1.4 million in 2015, then increased by 7.99% to $1.5 million in 2016, then decreased by 23.45% to $1.1 million in 2017.
  • Per Business Quant, the three most recent readings for SUPN's Non-Current Deffered Revenue are $1.1 million (Q4 2017), $1.2 million (Q3 2017), and $1.3 million (Q2 2017).